Stock info Abivax | Filter Basic-Info
Stock: Abivax (Paris small), ISIN: FR0012333284
| Last Price | 14.16 | Max Price | 19.20 |
| Min Price | 8.00 | 1 Year return | 129.13 |
| Sector | Health Care | Subsector | Biotechnology |
Sector Review Abivax
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 0 | 141,925 | 0.00 % |
| 2020 | 0 | 170,231 | 0.00 % |
| 2021 | 0 | 252,886 | 0.00 % |
| 2022 | 0 | 238,500 | 0.00 % |
| 2023 | 0 | 0 | 0.00 % |
Advice Abivax
No Records Found
News Abivax
No Records Found
Annual reports Abivax
No Records Found
Profile Abivax
Abivax
(FR0012333284)The past year was a relatively good year for Abivax investors
Over the last 12 months, that were loss-making period for the investors in Abivax, the stock lost around 56 percent. Over the period 2011-2016 the stock lost a modest 0 percent.
The global biotech companies gained around 59 percent over the period 2006-2016. Over the past 5 years the sector is 70 percent higher.
Over the past 5 years the French company paid out dividends.
Abivax financed with a quite low debt position
As per the end of 2015 the French company's balance sheet equaled 0 million euros. The total debt of the biotech company was at the end of 2015 0 million euros, which equals around percent of the total balance sheet.
All the company's financial reports are available here. More information about Abivax can be found it's website. .
Results Abivax
| Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Revenue |
0
|
0
|
0
|
0
|
0
|
|
| Costs |
16
|
14
|
11
|
16
|
31
|
38
|
| Profit |
-16
|
-14
|
-11
|
-16
|
-31
|
-38
|
| Margin of profit |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
| ROI |
-23.20
|
-26.25
|
-25.55
|
-55.05
|
-260.02
|
-804.07
|
Balance Abivax
| Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Equity |
69
|
55
|
44
|
29
|
12
|
5
|
| Debt |
8
|
6
|
10
|
25
|
40
|
67
|
| Total assets |
76
|
61
|
54
|
54
|
52
|
71
|
| Solvency |
90.15
|
89.95
|
81.61
|
53.17
|
22.77
|
6.55
|
| Cash |
39
|
23
|
17
|
13
|
10
|
29
|
| Cashflow |
-15
|
-16
|
-8
|
-15
|
-27
|
-30
|
| Employees |
0
|
0
|
0
|
0
|
0
|
|
| Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
| Cashflow / Debt |
-1.98
|
-2.56
|
-0.85
|
-0.58
|
-0.69
|
-0.45
|
Details Abivax
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
14.15
|
6.30
|
8.63
|
11.84
|
22.55
|
| Eps |
-1.48
|
-1.14
|
-1.56
|
-2.51
|
-2.62
|
| Price/earnings-ratio |
-9.56
|
-5.53
|
-5.53
|
-4.72
|
-5.40
|
| Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
| Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Book value |
5.65
|
4.45
|
2.82
|
0.97
|
0.33
|
| Market to book |
0.40
|
0.71
|
0.33
|
0.08
|
0.02
|
| Cashflow per stock |
-1.62
|
-0.86
|
-1.43
|
-2.26
|
-2.08
|
| Stocks |
10
|
10
|
10
|
12
|
14
|
| Market Cap |
136.58
|
62.18
|
87.81
|
144.22
|
202.59
|
Dividend Abivax
Price info Abivax
|
Date
|
Price
|
|---|---|
|
22 Apr 2024
|
14.16
|
|
18 Apr 2024
|
14.16
|
|
17 Apr 2024
|
14.00
|
|
09 Apr 2024
|
14.04
|
|
05 Apr 2024
|
14.06
|
|
03 Apr 2024
|
13.42
|
|
30 Mar 2024
|
13.40
|
|
22 Mar 2024
|
13.60
|
|
18 Mar 2024
|
12.68
|
|
15 Mar 2024
|
12.24
|
|
12 Mar 2024
|
12.42
|
|
11 Mar 2024
|
12.98
|
|
09 Mar 2024
|
12.98
|
|
07 Mar 2024
|
13.80
|
|
01 Mar 2024
|
12.66
|
|
29 Feb 2024
|
13.12
|
|
27 Feb 2024
|
13.50
|
|
22 Feb 2024
|
11.40
|
|
21 Feb 2024
|
11.06
|
|
20 Feb 2024
|
11.60
|
|
15 Feb 2024
|
11.32
|
|
14 Feb 2024
|
11.30
|
|
13 Feb 2024
|
11.70
|
|
09 Feb 2024
|
11.44
|
|
08 Feb 2024
|
11.44
|
|
07 Feb 2024
|
11.40
|
|
06 Feb 2024
|
11.44
|
|
05 Feb 2024
|
11.84
|
|
01 Feb 2024
|
12.08
|
|
31 Jan 2024
|
12.08
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
